A double-blinded extension study to provide adjuvant treatment with single agent HerceptinÃ?Â® or TX05 and assess continued safety and immunogenicity in subjects with HER2-positive early breast cancer following neoadjuvant treatment and surgical resection in Protocol TX05-03

Start Date04 Dec 2019

Sponsor / Collaborator

Tanvex Biologics, Inc.

NCT04109391 / CompletedPhase 3

A Double-blinded Extension Study to Provide Adjuvant Treatment With Single Agent Herceptin® or TX05 and Assess Continued Safety and Immunogenicity in Subjects With HER2-positive Early Breast Cancer Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03

This is an extension study to provide adjuvant treatment with single agent Herceptin or TX05 and assess continued safety and immunogenicity in subjects with HER2-positive early breast cancer following neoadjuvant treatment and surgical resection in Protocol TX05-03.

Start Date20 Aug 2019

Sponsor / Collaborator

Tanvex BioPharma USA, Inc.

CTRI/2019/01/017029 / CompletedPhase 3

A randomized, double-blind, parallel group, Phase III trial to compare the efficacy, safety, and immunogenicity of TX05 with HerceptinÃ?Â® in subjects with HER2 positive early breast cancer

Start Date11 Jan 2019

Sponsor / Collaborator

Tanvex Biologics, Inc.

100 Clinical Results associated with Trastuzumab biosimilar(Tanvex Biopharma, Inc.)

100 Translational Medicine associated with Trastuzumab biosimilar(Tanvex Biopharma, Inc.)

100 Patents (Medical) associated with Trastuzumab biosimilar(Tanvex Biopharma, Inc.)

Literatures (Medical) associated with Trastuzumab biosimilar(Tanvex Biopharma, Inc.)

18 Apr 2023·Molecules (Basel, Switzerland)

Molecular Dynamics Study on the Aggregation Behavior of Triton X Micelles with Different PEO Chain Lengths in Aqueous Solution.

Article

Author: Li, Xin ; Peng, Jin ; Xia, Qiying ; Wei, Yaoyao ; Song, Xiaoju ; Jiang, Yongkang ; Liu, Guokui

The aggregation structure of Triton X (TX) amphiphilic mols. in aqueous solution plays an important role in determining the various properties and applications of surfactant solutionsIn this paper, the properties of micelles formed by TX-5, TX-114, and TX-100 mols. with different poly(ethylene oxide) (PEO) chain lengths in TX series of nonionic surfactants were studied via mol. dynamics (MD) simulation.The structural characteristics of three micelles were analyzed at the mol. level, including the shape and size of micelles, the solvent accessible surface area, the radial distribution function, the micelle configuration, and the hydration numbersWith the increase of PEO chain length, the micelle size and solvent accessible surface area also increase.The distribution probability of the polar head oxygen atoms on the surface of the TX-100 micelle is higher than that in the TX-5 or TX-114 micelle.In particular, the tail quaternary carbon atoms in the hydrophobic region are mainly located at the micelle exterior.For TX-5, TX-114, and TX-100 micelles, the interactions between micelles and water mols. are also quite different.These structures and comparisons at the mol. level contribute to the further understanding of the aggregation and applications of TX series surfactants.

100 Deals associated with Trastuzumab biosimilar(Tanvex Biopharma, Inc.)

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	L01XC03	DB00072

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Breast Cancer 3	Phase 3	PE	Tanvex BioPharma USA, Inc.	28 Jun 2018
Breast Cancer 3	Phase 3	BY	Tanvex BioPharma USA, Inc.	28 Jun 2018
Breast Cancer 3	Phase 3	MX	Tanvex BioPharma USA, Inc.	28 Jun 2018
Breast Cancer 3	Phase 3	RU	Tanvex BioPharma USA, Inc.	28 Jun 2018
Breast Cancer 3	Phase 3	PH	Tanvex BioPharma USA, Inc.	28 Jun 2018
Breast Cancer 3	Phase 3	GE	Tanvex BioPharma USA, Inc.	28 Jun 2018
Breast Cancer 3	Phase 3	HU	Tanvex BioPharma USA, Inc.	28 Jun 2018
Breast Cancer 3	Phase 3	CL	Tanvex BioPharma USA, Inc.	28 Jun 2018
Breast Cancer 3	Phase 3	UA	Tanvex BioPharma USA, Inc.	28 Jun 2018
Breast Cancer 3	Phase 3	IN	Tanvex BioPharma USA, Inc.	28 Jun 2018

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04109391 (TX05-03e \| TX05-03, CTgov)	Phase 3	HER2 Positive Breast Cancer \| Early Stage Breast Carcinoma \| Breast Cancer 3	338	TX05 (trastuzumab)	iytrdcwjtz(uyonkcvlqa) = hdlvluxpps hxshrpfvvb (upgwfbtwhe, wrzoexicrr - apkpwqqabs) View more	-	26 Oct 2022
NCT04109391 (TX05-03, ASCO2022) Manual	Phase 3	HER2 Positive Breast Cancer Neoadjuvant HER2 Positive	338	TX05	(mbkfllokvm) = jilivocswu erroftwujt (iblnhmlfiv ) View more	Positive	08 Jun 2022
				trastuzumab+TX05	(mbkfllokvm) = htekmyioaq erroftwujt (iblnhmlfiv ) View more
NCT03556358 (CTgov)	Phase 3	HER2 Positive Breast Cancer \| Breast Cancer 3	809	CYCLOPHOSPHAMIDE+Paclitaxel+Epirubicin+TX05 (trastuzumab) (TX05 (Trastuzumab))	omraocsipu(tozukcdrem) = ktrqinwqoq ybfnnfjhgb (wzyngscwcp, quowljwouu - ztftjsracw) View more	-	14 Jan 2022
				Herceptin®+CYCLOPHOSPHAMIDE+Paclitaxel+Epirubicin (Herceptin®)	omraocsipu(tozukcdrem) = gbpcrtwdnz ybfnnfjhgb (wzyngscwcp, lfkvruujwi - ivzlkvmjgr) View more
EUCTR2017-004190-13-BG \| NCT03556358 (TX05-03, ESMO2021) Manual	Phase 3	HER2 Positive Breast Cancer HER2 Positive	809	epirubicin+cyclophosphamide+paclitaxel+TX05	(xxlvsjfzqr) = vtjskarqnh lmqpjvfskw (ngheblyshh ) View more	Similar	16 Sep 2021
				epirubicin+cyclophosphamide+paclitaxel+trastuzumab (TRA)	(xxlvsjfzqr) = ffekvrznke lmqpjvfskw (ngheblyshh ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis